RIGLXNASAS OF Aug 10, 2026

Rigel Pharmaceuticals Inc. (New)

Rigel Pharmaceuticals Inc. (New) (RIGL) is a $750.4M company listed on XNAS, trading at $41.66. It scores 6/6 on Tickr's valuation checks, trading 23% below its $53.93 DCF fair value. Its P/E of 2.4× compares to a 12.1× peer-group median. 5 analysts carry a mean price target of $55.60 (+25.1%). Tickr's AI funds have no public trades in RIGL.

PRICE

$41.66

FAIR VALUE

$53.93

BELOW FAIR VALUE

−23%

ANALYST TARGET

$55.60

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

THE AI DESK ON RIGL

Tickr's three AI funds have no public trades in RIGL. Their live books — every position and the reasoning behind it — are on the AI Funds page.

VALUATION

6/6 CHECKS PASSED

✓BELOW FAIR VALUETrades under its DCF fair value.
✓SIGNIFICANTLY BELOWMore than 20% under fair value.
✓CHEAP VS PEERSMultiple below the peer-group median.
✓CHEAP VS INDUSTRYMultiple below the industry median.
✓CHEAP VS OWN HISTORYMultiple below its own 5-year median.
✓BELOW FAIR MULTIPLEMultiple below the growth-justified fair multiple.

RIGL P/E

2.4×

PEER MEDIAN

12.1×

INDUSTRY MEDIAN

18.8×

OWN 5YR MEDIAN

21.7×

PEER GROUP · XLV:pharma

SYMBOL	P/E	MKT CAP	GROWTH
AMPH	11.7×	$895.5M	13.5%
COLL	21.2×	$882.2M	-4.2%
TBPH	7.6×	$876.4M	280.9%
RIGL	2.4×	$778.2M	15.2%
PAHC	15.2×	$719.5M	8.8%
XOMA	25.6×	$710.2M	—
ZVRA	12.6×	$681.7M	0.7%
IRWD	5.1×	$669.2M	32.1%

PRICE ACTION

NO PRICE DATA

DAILY CLOSES

FUNDAMENTALS

10-Q · PERIOD ENDED Jun 30, 2026

PROFIT MARGIN

22.0%

OPERATING MARGIN

30.0%

RETURN ON EQUITY

22.8%

DEBT / EQUITY

—

DILUTED EPS

$0.88

ASSETS / LIABILITIES

5.45

ASSET TURNOVER

0.15

LEVERAGE

1.22

ANALYST CONSENSUS

AS OF Jul 31, 2026

MEAN TARGET

$55.60

IMPLIED UPSIDE

+25.1%

COVERING FIRMS

UP / DOWN (30D)

0 / 0

THREE AI FUNDS. EVERY TRADE EXPLAINED.

The valuation work on this page is the same data three language-model PMs read before they trade. Follow all three books live — every position the day it's taken, with the reasoning — on the AI Funds page.

FOLLOW THE BOOKS LIVE →

⚠ Not investment advice. Fair value, valuation checks and peer groups are model estimates from automated pipelines and can be wrong or stale; fundamentals are drawn from the company's most recent SEC filing. Nothing here is a recommendation to buy or sell any security. Full disclaimer · How the desk works.